Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.76 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL8911713 | 0.93 | TRPA1 (0.80) | TRPA1CSNK2A1TP53TDP1GAA | |
| Carbamic Acid SCHEMBL3371914 | 0.88 | TRPA1 (0.73) | TRPA1CSNK2A1TP53TDP1GAA | |
| SCHEMBL12388 | 0.87 | — | — | |
| SCHEMBL29406334 | 0.87 | — | — | |
| Formaldehyde SCHEMBL27665137 | 0.85 | TRPA1 (0.84) | TRPA1CSNK2A1TP53TDP1GAA | |
| SCHEMBL27803153 | 0.85 | TRPA1 (0.94) | TRPA1CSNK2A1TP53TDP1GAA | |
| Ammonia Solution, Strong SCHEMBL27929342 | 0.85 | TRPA1 (0.94) | TRPA1CSNK2A1TP53TDP1GAA | |
| SCHEMBL1937639 | 0.85 | TRPA1 (0.94) | TRPA1CSNK2A1TP53TDP1GAA | |
| Methane SCHEMBL5950714 | 0.85 | TRPA1 (0.94) | TRPA1CSNK2A1TP53TDP1GAA | |
| SCHEMBL27823792 | 0.85 | TRPA1 (0.94) | TRPA1CSNK2A1TP53TDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010584-B2 | Treatment of depressive disorders | WEST VIRGINIA UNIVERSITY (US) | 2018-07-03 | — | — | US | claimed |
| EP-3332797-A2 | THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS AND OTHER RELATED SUBSTANCES ON HEAD TRAUMA-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY | Blanchette Rockefeller Neurosciences Institute (US) | 2018-06-13 | — | — | EP | claimed |
| EP-2737904-A2 | Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury | Blanchette Rockefeller Neurosciences Institute (US) | 2014-06-04 | — | — | EP | claimed |
| US-20130165375-A1 | TREATMENT OF DEPRESSIVE DISORDERS | BLANCHETTE ROCKEFELLER NEUROSCIENCE INSTITUTE (US) | 2013-06-27 | — | — | US | claimed |
| US-20130165453-A1 | THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON ISCHEMIA/STROKE-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE | 2013-06-27 | — | — | US | claimed |
| US-20110288022-A1 | TREATMENT OF DEPRESSIVE DISORDERS | WEST VIRGINIA UNIVERSITY | 2011-11-24 | — | — | US | claimed |
| CN-101848726-A | The memory impairment that bryostatin, bryostatin analog and other related substances cause head trauma and the curative effect of brain injury | BRNI NEUROSCIENCES INST | 2010-09-29 | — | — | CN | claimed |
| US-7803400-B2 | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2010-09-28 | — | — | US | claimed |
| CN-101678080-A | Bryostatin, bryostatin analog and other related substances to ischemia/in the curative effect of wind-induced memory impairment and brain injury | BRNI NEUROSCIENCES INST | 2010-03-24 | — | — | CN | claimed |
| EP-2121000-A2 | THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON HEAD TRAUMA-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY | Blanchette Rockefeller Neurosciences Institute (US) | 2009-11-25 | — | — | EP | claimed |
| EP-2121001-A2 | THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON ISCHEMIA/STROKE-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY | Blanchette Rockefeller Neurosciences Institute (US) | 2009-11-25 | — | — | EP | claimed |
| US-20090036514-A1 | Therapeutic effects of Bryostatins, Bryologs, and other related substances on Ischemia/stroke-induced memory impairment and brain injury | WEST VIRGINIA UNIVERSITY | 2009-02-05 | — | — | US | claimed |
| WO-2008143880-A2 | THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON HEAD TRAUMA-INDUCED MEMORY IMPAIRMENT AND TRAUMATIC BRAIN INJURY | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2008-11-27 | — | — | WO | claimed |
| US-20080207742-A1 | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury | COGNITIVE RESEARCH ENTERPRISES, INC. | 2008-08-28 | — | — | US | claimed |
| WO-2008100450-A2 | THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON ISCHEMIA/STROKE-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2008-08-21 | — | — | WO | claimed |
| WO-2008100449-A2 | THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON HEAD TRAUMA-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2008-08-21 | — | — | WO | claimed |
| CN-122012625-A | Viral vector production | 牛津生物医学（英国）有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3967299-B1 | PKC ACTIVATORS AND COMBINATIONS THEREOF FOR TREATING ALZHEIMER DISEASE | COGNITIVE RES ENTERPRISES INC (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20080003181-A1 | Treatment of depressive disorders | WEST VIRGINIA UNIVERSITY | 2008-01-03 | — | — | US | disclosed |
| US-20080004332-A1 | Methods for alzheimer's disease treatment and cognitive enhancement | ALKON DANIEL L | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165453-A1 | THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON ISCHEMIA/STROKE-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY | BDNF, NGF, NTRK2 | TRPA1 2856/4885CSNK2A1 149/4885TP53 3071/4885 |
| US-20110288022-A1 | TREATMENT OF DEPRESSIVE DISORDERS | FGF1, FGFR1, FGFR3 | TRPA1 2980/4885CSNK2A1 127/4885TP53 4215/4885 |
| US-20080207742-A1 | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury | BDNF, NGF, NTRK2 | TRPA1 2723/4885CSNK2A1 291/4885TP53 3146/4885 |
| US-20090036514-A1 | Therapeutic effects of Bryostatins, Bryologs, and other related substances on Ischemia/stroke-induced memory impairment and brain injury | BDNF, NGF, NTRK2 | TRPA1 2856/4885CSNK2A1 149/4885TP53 3071/4885 |
| US-20080004332-A1 | Methods for alzheimer's disease treatment and cognitive enhancement | BACE1, PRKCH, GSAP | TRPA1 4384/4885CSNK2A1 1643/4885TP53 1984/4885 |
| US-20130165375-A1 | TREATMENT OF DEPRESSIVE DISORDERS | FGF1, FGFR1, FGFR3 | TRPA1 2976/4885CSNK2A1 126/4885TP53 4260/4885 |
| US-20080003181-A1 | Treatment of depressive disorders | FGF1, FGFR1, FGFR3 | TRPA1 2980/4885CSNK2A1 127/4885TP53 4215/4885 |
| US-10010584-B2 | Treatment of depressive disorders | FGF1, FGFR1, FGFR3 | TRPA1 2976/4885CSNK2A1 126/4885TP53 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.